 |
Vol.46 No.4 contents | Japanese/English |
 | Full Text of PDF (304K) Article in Japanese |
- Original Article -
Expression of TNF-related Apoptosis-inducing Ligand (TRAIL) and TRAIL Receptor 1 on Cancer and Normal Tissues in Patients with Non-small Cell Lung Cancer
Tatsuo Kawashima1, Ryutaro Matsumura1, Keiko Umemiya1, Sayaka Kawashima1, Kyoko Kikkawa1, Yumiko Nishi1, Tsukane Goto1, Yasuo Matsuzawa1, Hisao Tomioka1, Hisami Yamakawa21Department of Internal Medicine, Toho University School of Medicine, Sakura Hospital, Japan, 2Division of Thoracic Surgery, National Chiba-higashi Hospital, Japan
Objective. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces apoptosis in various in vitro tumor studies. However de novo expression of TRAIL and TRAIL-receptor 1 (TRAIL-R1) in cancer tissues is not well documented, and few data are available on their effect on the clinical outcome of non-small cell lung cancer (NSCLC) patients. The aim of this study was to evaluate the expression of TRAIL and TRAIL-R1 proteins in cancer tissues surgically resected from patients with NSCLC by scoring the immunoreactivity, and to examine the correlation between the expression of these proteins and clinical findings of NSCLC. Methods. Cancer tissues and normal tissues were obtained from patients with NSCLC. The expression of TRAIL and TRAIL-R1 proteins was examined by immunohistochemical studies. Results. Significantly higher immunostaining scores for TRAIL and TRAIL-R1 were observed in cancer tissues compared with normal tissues of patients with NSCLC (P<0.0001 for both). There was a significantly positive correlation between the immunostaining score of TRAIL or TRAIL-R1 and pathological T-factor in these patients (P=0.021 and P=0.009, respectively). Conclusion. The majority of NSCLCs expressed TRAIL and TRAIL-R1, which may play a role in regulating the progression of NSCLC.
key words: Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), Tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1), Non-small cell lung cancer (NSCLC), Immunohistochemistry
Received: February 8, 2006
Accepted: April 26, 2006
JJLC 46 (4): 321-327, 2006
